Epilepsie Instellingen Nederland Stichting
- Address
- lock Available on a paid plan
Neurology and Nervous System Diseases
At Epilepsie Instellingen Nederland Stichting in Zwolle, clinical research focuses on neurological disorders affecting sleep and seizure control. The studies are designed to assess new and existing therapies for improving symptoms, safety, and long-term treatment benefit in people living with complex conditions of the nervous system.
- Narcolepsy and Idiopathic Hypersomnia research aimed at reducing excessive daytime sleepiness and improving daily functioning
- Epilepsy studies in Dravet syndrome, Lennox-Gastaut syndrome, and developmental and epileptic encephalopathies exploring better seizure control
- Trials in refractory focal onset epilepsy evaluating treatment effectiveness and tolerability in difficult-to-manage seizures
Overall, the site is contributing to research on both sleep disorders and rare epileptic conditions, with a strong emphasis on testing therapies that may offer safer and more effective long-term care.
Sleep Disorders
A major part of the clinical trial portfolio at this site centers on narcolepsy and idiopathic hypersomnia. These studies are focused on understanding whether new treatments can lessen excessive daytime sleepiness and support better alertness, energy, and quality of life for patients.
- Narcolepsy Type 1 and Narcolepsy Type 2 treatment research
- Idiopathic hypersomnia studies assessing symptom relief and tolerability
- Clinical evaluation of therapies intended to improve wakefulness in people with persistent sleepiness
This work reflects a broader effort to improve care for people whose daily lives are affected by chronic sleep-wake disorders.
Epilepsy and Rare Seizure Disorders
The site also conducts research in epilepsy and related rare seizure disorders, including CDKL5 deficiency disorder, Dravet syndrome, Lennox-Gastaut syndrome, and developmental and epileptic encephalopathies. These trials are aimed at finding therapies that may help reduce seizure burden and support longer-term disease management.
- Studies in CDKL5 deficiency disorder examining seizure control and treatment benefit
- Research in Dravet syndrome and Lennox-Gastaut syndrome focused on safety and effectiveness
- Trials in developmental and epileptic encephalopathies evaluating new options for difficult-to-treat seizures
This area highlights ongoing efforts to improve outcomes for patients with severe and often treatment-resistant epileptic conditions.
Refractory Focal Epilepsy
Another important research focus is refractory focal onset epilepsy, where studies are assessing whether new therapies can help people whose seizures remain difficult to control. The main purpose is to evaluate treatment effectiveness while also monitoring safety and tolerability in everyday clinical care.
- Research on seizure reduction in refractory focal onset epilepsy
- Evaluation of treatment safety for patients with persistent focal seizures
- Clinical trials exploring better options for people with limited response to standard care
This work adds to the site’s broader neurology portfolio by addressing a challenging form of epilepsy that can significantly affect daily life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Alkermes Inc.4active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Alkermes Inc.6trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Epilepsie Instellingen Nederland Stichting
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | Alkermes Inc. | Phase II | Not Recruiting | Jan 2025 | Jul 2025 |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alks 2680 | 6 | Unknown | 2025-01-17 | 2026-07-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.